Glycobiology of ocular angiogenesis

Glycobiology

Volumn 24, Issue 12, 2014, Pages 1275-1282

  IMarkowska, Anna ^a,b   Cao, Zhiyi ^a,c   Panjwani, Noorjahan ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ymir Genomics LLC   (United States)

^c NEW ENGLAND EYE CENTER   (United States)

Author keywords

Angiogenesis; Choroidal neovascularization; Corneal neovascularization; Galectin 3; Glycans; Glycosylation; Integrins; Neovascularization; Retinal neovascularization

Indexed keywords

CARBOHYDRATE; CELL SURFACE RECEPTOR; GALAPTIN; GALECTIN; GALECTIN 3;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; CELL ACTIVATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CORNEA NEOVASCULARIZATION; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GLYCOBIOLOGY; HUMAN; IRIS; MAMMAL CELL; MOLECULAR RECOGNITION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT; EYE; GLYCOSYLATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

EYE; GALECTINS; GLYCOMICS; GLYCOSYLATION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84941126753     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu078     Document Type: Review

References (100)

1. Adamis AP, Aiello LP, D'Amato RA. 1999. Angiogenesis and ophthalmic disease. Angiogenesis. 3:9-14.
2. Adamis AP, Miller J W, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT. 1994. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 118:445-450.
3. Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB. 2007. Retinal and choroidal microangiopathies: Therapeutic opportunities. Microvasc Res. 74:131-144.
4. Aiello LP, Ave ry RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE and, et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal dis orders. N Engl J Med. 331:1480-1487.
5. Asahara T,Chen D,Takahashi T,Fujikawa K,Kearney M,Magner M,Yancopoulos GD,Isner JM 1998 Tie2 receptor ligands, angiopoietin-1 and angiopoieti n-2, modulate VEGF-induced postnatal neovascularization Circ Res. 83 233-240.
6. Breen EC. 2007. VEGF in biological control. J Cell Biochem. 102:1358-1367.
7. Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW. 2007. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res. 2007:51837.
8. Cao R, Brakenhielm E, Li X, Pietras K, Widenfalk J, Ostman A, Eriksson U, Cao Y. 2002. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-Alphaalpha and-Alphabeta re ceptors. FASEB J. 16:1575-1583.
9. Chang JH, Gabison EE, Kato T, Azar DT. 2001. Corneal neovascularization. Curr Opin Ophthalmol. 12:242-249.
10. Contois L, Akalu A, Bro oks PC. 2009. Integrins as " functional hubs" in the regulation of pathological angiogenesis. Semin Cancer Biol. 19:318-328.
11. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, Garcia-Vallejo JJ, Ouyang J, et al. 2014. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 156:744-758.
12. Cross MJ, Claesson-Welsh L. 2001. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 22:201-207.
13. Csaky KG, Baffi JZ , Byrnes GA, Wolfe JD, Hilmer SC, Flippin J, Cousins SW. 2004. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Ey e Res. 78:1107-1116.
14. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW. 2004. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 113:1040-1050.
15. Delgado VM, Nugnes LG, Colombo L L, Troncoso MF, Fernandez MM, Malchiodi EL, Frahm I, Croci DO, Compagno D, Rabinovich GA, et al. 2011. Modulation of endothelial cell migration and angiogenesis: A novel function for the "tandem-repeat " lectin gale ctin-8. FASEB J. 25:242-254.
16. Dennis K, Uittenbogaard M, Chiaramello A, Moody SA. 2002. Cloning and characterization of the 5?-flanking region of the rat neuron-specific Class III beta-tubulin gene. Gene. 294:269-277.
17. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. 2007. Ocular neovascularization: Basic mechanisms and therapeutic advances. Surv Ophthalmol. 52:3-19.
18. Eco nomopoulou M, Bdeir K, Cines DB, Fogt F, Bdeir Y, Lubkowski J, Lu W, Preissner KT, Hammes HP, Chavakis T. 2005. Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood. 106:3831-3838.
19. Fernandez-Robredo P, Sancho A, Johnen S, Recalde S, Gama N, Thumann G, Groll J, Garcia-Layana A. 2014. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol. 2014:510285.
20. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. 1996. Basic fibroblast growth factor and vascular endothelial growth fact or are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 122:393-403.
21. FriedlanderM. 2007. Fibrosis and diseases of the eye. J Clin Invest. 117:576-586.
22. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA. 1996. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 93:9764-9769 .
23. Fukushi J, Makagiansar IT, Stallcup WB. 2004. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell. 15:3580-3590.
24. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. 2002. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 133:70-77.
25. Garmy-Susini B, Varner JA. 2008. Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol. 6:155-163.
26. Gaudric A, N'Guyen T, Moenner M, Glacet-Bernard A, Barritault D. 1992. Quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model. Ophthalmic Res. 24:181-188.
27. Gurel Z, Sieg KM, Shallow KD, Sorenson CM, Sheibani N. 2013. Retinal O-linked N-Acetylglucosamine protein modifications: Implications for postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol Vis. 19:1047-1059.
28. Hafez SA, Caceci T, Freeman LE, Panter KE. 2007. Angiogenesis in the caprine caruncles in non-pregnant and pregnant normal and swainsoninetreated does. Anat Rec (Hoboken). 290:761-769.
29. Henderson N C, MacKinnon AC, Rooney C, Sethi T. 2012. Galectin-3: A central regulator of chronic inflammation and tissue fibrosis. In: Klyosov AA, Traber PG, editors. Galectins and Disease Implications for Targeted Therapeutics.Washington: Americ an Chemical Society, pp. 377-390.
30. Henderson NC, MacKinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T. 2008. Galectin-3 expression and secretion links macropha ges to the promotion of renal fibrosis. Am J Pathol. 172:288-298.
31. Henderson NC, MacKinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T. 2006. Gal ectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 103:5060-5065.
32. Hera R, Keramidas M, Peoc'h M, Mouillon M, Romanet JP, Feige JJ. 2005. Expression of VEGF and angiopoietin s in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol. 139:589-596.
33. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. 2004. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549-580.
34. Honda S, Nagai T, Negi A. 2009. Anti-Angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced c horoidal neovascularization in mice. Graefes Arch Clin Exp Ophthalmol. 247:515-522.
35. Hsieh SH, Ying NW, Wu MH, Chiang WF, Hsu CL, Wong TY, Jin YT, Hong TM, Chen YL. 2008. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene. 27:3746-3753.
36. Iliaki E, Poulaki V, Mitsiades N, Mitsiades CS, Miller JW, G ragoudas ES. 2009. Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy. Invest Ophthalmol Vis Sci. 50:4898-4904.
37. Jia W, Kidoya H, Yamakawa D, Naito H, Takakura N. 2013. Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am J Pathol. 182:1821-1831.
38. Jo DH, Kim S, Kim D, Kim JH, Jon S. 2014. VEGF-binding aptides and the inhibition of choroidal and retinal neovascularization. Biomaterials. 35:3052-3059.
39. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. 1995. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 36:182-191.
40. Kliffen M, van der Schaft TL, Mooy CM, de Jong PT. 1997. Morphologic changes in age-related maculopathy. Microsc Res Tech. 36:106-122.
41. Klotz O, Park JK, Pleyer U, Hartmann C, Baatz H. 2000. Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat. Graefes Arch Clin Exp Ophthalmol. 238:88-93.
42. Knighton DR, Phillips GD, Fiegel VD. 1990. Wound healing angiogenesis: Indirect stimulation by basic fibroblast growth factor. J Trauma. 30:S134-S144.
43. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. 2002. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment . Arch Ophthalmol. 120:338-346.
44. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I, Van Noorden CJ, Goldschmeding R, Schlingemann RO. 2008. T he angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE. 3:e2675.
45. Kvanta A, Algvere PV, Berglin L, Seregard S. 1996. Subfoveal fibrovascular membranes in age-related ma cular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 37:1929-1934.
46. Lima e Silva R, Shen J, Hackett SF, Kachi S, Akiyama H, Kiuchi K, Yokoi K, Hatara MC, Lauer T, Aslam S, et al. 200 7. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J. 21:3219-3230.
47. Ljubimov AV, Huang ZS, Huang GH, Burgeson RE, Gullberg D, Miner JH, Ninomiya Y, Sado Y, Kenney MC. 1998. Human corneal epithelial basement membrane and integrin alterations in diabetes and diabetic retinopathy. J Histochem Cytochem. 46:1033-1041.
48. Lopez PF,Sippy BD,Lambert HM,Thach AB,Hinton DR 1996 Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes Invest Ophthalmol Vis Sci. 37 855-868.
49. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. 1996. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine mode l. Lab Invest. 75:563-573.
50. Luo B, Soesanto Y, McClain DA. 2008. Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Bi ol. 28:651-657.
51. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, et al. 2002. Revascularization of ischemic tissues by PlG F treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 8:831-840.
52. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. 2012. Critical role of O-Linked beta-N-Acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 287: 11070-11081.
53. Machado CM, Andrade LN, Teixeira VR, Costa FF, Melo C M, dos Santos SN, Nonogaki S, Liu FT, Bernardes ES, Camargo AA, et al. 2014. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFbeta1-induced macrophages. Cancer Med. 3:201-214.
54. MacK innon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T. 2008. Regulation of alternative macrophage activation by galectin-3. J Immunol. 180: 2650-2658.
55. MacKinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, et al. 2012. Regulation of transforming growth factor-b eta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 185:537-546.
56. Markowska AI, Jefferies KC, Panjwani N. 2011. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem. 286:2991 3-29921.
57. Markowska AI, Liu FT, Panjwani N. 2010. Galectin-3 is an important mediator of VEGF-And bFGF-mediated angiogenic response. J ExpMed. 207:1981-1993.
58. Mauris J, Woodward AM, Cao Z, Panjwani N, Argueso P. 2014. Molecular basis for MMP9 induction and disruption of epithelial cell-cell contacts by galectin-3. J Cell Sci. 127:3141-3148.
59. Mimura T, Amano S, Usui T, Ka ji Y, Oshika T, Ishii Y. 2001. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Exp Eye Res. 72:71-78.
60. Mitchell P. 2011 . A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: Comparison of ranibizumab and bevacizumab. Curr Med Res Opin. 27:1465-1475.
61. Morello CM . 2007. Etiology and natural history of diabetic retinopathy: An overview. Am J Health Syst Pharm. 64:S3-S7.
62. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. 2002. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 43:2428-2434.
63. Muether PS, Dell S, Kociok N, Zahn G, Stragies R, Vossmeye r D, Joussen AM. 2007. The role of integrin alpha5beta1 in the regulation of corneal neovascularization. Exp Eye Res. 85:356-365.
64. Nakao S, Hata Y, MiuraM, Noda K, Kimura YN, Kawahara S, Kita T, Hisatomi T, Nakazawa T, Jin Y, et al. 2007. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: Role of nuclear factor-kappaB-Activated stromal cells in inflammatory angiogenesis. Am J Pathol. 171:1058-1065.
65. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. 2002. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus p ectin. J Natl Cancer Inst. 94:1854-1862.
66. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 156:899-909.
67. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A. 2010. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer. 127:2530-2541.
68. Nguyen M, Folkman J, Bischoff J. 1992. 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. Analysis of N-linked oligosaccharides in bovine capillary endothelial cells. J Biol Chem. 267:26157-26165.
69. Ogata N,Matsuoka M,Matsuyama K,Shima C,Tajika A,Nishiyama T,Wada M,Jo N,Higuchi A,Minamino K,et al 2007 Plasma concentration of pig ment epithelium-derived factor in patients with diabetic retinopathy J Clin Endocrinol Metab. 92 1176-1179.
70. Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M. 2002. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 43:1168-1175.
71. Otrock ZK, Makarem JA, Shamseddine AI. 2007. Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol Dis. 38:258-268.
72. Patel RD, Momi RS, Hariprasad SM. 2011. Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol. 26:372-379.
73. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Schraermeyer U. 2007. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 143:995-1002.
74. Philipp W, Speicher L, Humpel C. 2000. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 41:2514-2522.
75. Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ , Passaniti A. 1995. The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 55:2920-2926.
76. Qazi Y, Maddula S, Ambati BK. 2009. Mediators of ocular angiogenesis. J Genet. 88:495-515.
77. Riecke B, Chavakis E, Bretzel RG, Linn T, Preissner KT, Brownlee M, Hammes HP. 2001. Topical application o f integrin antagonists inhibits proliferative retinopathy. Horm Metab Res. 33:307-311.
78. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. 2013. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology. 120:2292-2299.
79. Rogers MS, Birsner AE, D'Amato RJ. 2007. The mouse cornea micropocket angiogenesis assay. Nat Protoc. 2:2545-2550.
80. Roskoski R, Jr. 2008. VEGF receptor protein-tyrosine kinases: Structure and regulation. Biochem Biophys Res Commun. 375:287-291.
81. Saishin Y, Silva RL, Callahan K, Schoch C, Ahlheim M, Lai H, Kane F, Brazzell RK, Bodmer D, Campochiaro PA. 2003. Pe riocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci. 44:4989-4993.
82. Schraermeyer U, Julien S. 2012. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol. 250:1303-1313.
83. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, Yamada E, Derevjanik NL, LaRochelle W, Zack DJ, et al. 2000. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol. 157:995-1005.
84. Shakiba Y, Mansouri K, Arshadi D, Rezaei N. 2009. Corneal neovascularization: Molecular events and therapeutic options. Recent Pat Inflamm Allergy Drug Discov. 3:221-231.
85. Silva R, D'Amico G , Hodivala-Dilke KM, Reynolds LE. 2008. Integrins: The keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol. 28:1703-1713.
86. Sivak JM, Ostriker AC,Woolfenden A, Demirs J, Cepeda R, Lo ng D, Anderson K, Jaffee B. 2011. Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization. J Biol Chem. 286:44965-44975.
87. Spilsbury K, Garr ett KL, Shen WY, Constable IJ, Rakoczy PE. 2000. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 157:135-144.
88. Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK, Liu FT, Thorpe SR, Gardiner TA. 2005. Impaired retinal angiogenesis in diabetes: Role of advanced glycation end product s and galectin-3. Diabetes. 54:785-794.
89. Thijssen VL, Poirier F, Baum LG, Griffioen AW. 2007. Galectins in the tumor endothelium: Opportunities for combined cancer therapy. Blood. 110: 2819-2827.
90. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, et al. 2006. Galectin-1 is essential in tumor angiogenesis and i s a target for antiangiogenesis therapy. Proc Natl Acad Sci USA. 103:15975-15980.
91. Tiganis T, Leaver DD, Ham K, Friedhuber A, Stewart P, Dziadek M. 1992. Functional and morphological changes indu ced by tunicamycin in dividing and confluent endothelial cells. Exp Cell Res. 198:191-200.
92. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS. 2006. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 141:456-462.
93. Umeda N, Kachi S, Akiyama H, Zahn G, Vossm eyer D, Stragies R, Campochiaro PA. 2006. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol. 69:1820-1828.
94. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, Klaassen I, Schlingemann RO. 2012. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizu mab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 96:587-590.
95. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ. 1996. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 80:363-366.
96. Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE. 2006. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prema turity. Invest Ophthalmol Vis Sci. 47:1600-1605.
97. Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF, Schlingemann RO. 2002. Altered expression patterns of VEGF receptors in human diabetic retina an d in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci. 43:849-857.
98. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. 2012. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology. 119:1621-1627.
99. Yoshida T, Gong J, Xu Z, Wei Y, Duh EJ. 2012. Inhibition of pathological retinal angiogenesis by the integrin alphavbeta3 antagonist tetraiodothyroacetic acid (tetrac). Exp Eye Res. 94:41-48.
100. Zhang H, Li C, Baciu PC. 2002. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 43: 955-962.